These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1591094)

  • 1. Dose intensity of chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil in the elderly with advanced breast cancer.
    Beex LV; Hermus AR; Pieters GF; van Hoesel QG; Nooy MA; Mignolet F
    Eur J Cancer; 1992; 28(2-3):686-90. PubMed ID: 1591094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
    J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
    Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
    Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
    Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
    J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.
    Nuzzo F; Morabito A; De Maio E; Di Rella F; Gravina A; Labonia V; Landi G; Pacilio C; Piccirillo MC; Rossi E; D'Aiuto G; Thomas R; Gori S; Colozza M; De Placido S; Lauria R; Signoriello G; Gallo C; Perrone F; de Matteis A
    Crit Rev Oncol Hematol; 2008 May; 66(2):171-80. PubMed ID: 18160303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
    von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
    Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
    Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
    J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer.
    Hurria A; Hurria A; Brogan K; Panageas KS; Pearce C; Norton L; Jakubowski A; Howard J; Hudis C
    Drugs Aging; 2005; 22(9):785-91. PubMed ID: 16156682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent sequencing of full-dose CMF chemotherapy and radiation therapy in early breast cancer has no effect on treatment delivery.
    Faul C; Brufsky A; Gerszten K; Flickinger J; Kunschner A; Jacob H; Vogel V
    Eur J Cancer; 2003 Apr; 39(6):763-8. PubMed ID: 12651201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
    Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
    Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
    Ejlertsen B; Mouridsen HT; Jensen MB
    Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.
    Jodrell DI; Smith IE; Mansi JL; Pearson MC; Walsh G; Ashley S; Sinnett HD; McKinna JA
    Br J Cancer; 1991 May; 63(5):794-8. PubMed ID: 2039705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
    Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
    J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
    Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
    J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
    Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
    J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808).
    Engelsman E; Klijn JC; Rubens RD; Wildiers J; Beex LV; Nooij MA; Rotmensz N; Sylvester R
    Eur J Cancer; 1991; 27(8):966-70. PubMed ID: 1832904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience.
    De Maio E; Gravina A; Pacilio C; Amabile G; Labonia V; Landi G; Nuzzo F; Rossi E; D'Aiuto G; Capasso I; Rinaldo M; Morrica B; Elmo M; Di Maio M; Perrone F; de Matteis A
    BMC Cancer; 2005 Mar; 5():30. PubMed ID: 15790416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
    Fogelman I; Blake GM; Blamey R; Palmer M; Sauerbrei W; Schumacher M; Serin D; Stewart A; Wilpshaar W
    Osteoporos Int; 2003 Dec; 14(12):1001-6. PubMed ID: 14530912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer.
    Bonadonna G; Zambetti M; Moliterni A; Gianni L; Valagussa P
    J Clin Oncol; 2004 May; 22(9):1614-20. PubMed ID: 15117983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women.
    Taylor SG; Gelman RS; Falkson G; Cummings FJ
    Ann Intern Med; 1986 Apr; 104(4):455-61. PubMed ID: 3513684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.